Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS??? EQUITY (DEFICIT)

v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT) - USD ($)
$ in Thousands
Total
Common stock and capital in excess of par value
Accumulated deficit
Balance at beginning of period (in shares) at Dec. 31, 2020 110,851,000    
Balance at beginning of period at Dec. 31, 2020 $ 201,531    
Balance at end of period (in shares) at Sep. 30, 2021 110,851,000    
Balance at end of period at Sep. 30, 2021 $ 201,531    
Balance at beginning of period (in shares) at Dec. 31, 2020   17,948,000  
Balance at beginning of period at Dec. 31, 2020 (140,363) $ 12,118 $ (152,481)
Total stockholders’ equity      
Issuance of common stock upon exercise of stock options (in shares)   2,053,000  
Issuance of common stock upon exercise of stock options 1,822 $ 1,822  
Stock-based compensation expense 4,919 $ 4,919  
Net loss (33,803)   (33,803)
Balance at end of period (in shares) at Sep. 30, 2021   20,001,000  
Balance at end of period at Sep. 30, 2021 $ (167,425) $ 18,859 (186,284)
Balance at beginning of period (in shares) at Jun. 30, 2021 110,851,000    
Balance at beginning of period at Jun. 30, 2021 $ 201,531    
Balance at end of period (in shares) at Sep. 30, 2021 110,851,000    
Balance at end of period at Sep. 30, 2021 $ 201,531    
Balance at beginning of period (in shares) at Jun. 30, 2021   18,940,000  
Balance at beginning of period at Jun. 30, 2021 (161,594) $ 15,054 (176,648)
Total stockholders’ equity      
Issuance of common stock upon exercise of stock options (in shares)   1,061,000  
Issuance of common stock upon exercise of stock options 1,018 $ 1,018  
Stock-based compensation expense 2,787 $ 2,787  
Net loss (9,636)   (9,636)
Balance at end of period (in shares) at Sep. 30, 2021   20,001,000  
Balance at end of period at Sep. 30, 2021 $ (167,425) $ 18,859 (186,284)
Balance at beginning of period (in shares) at Dec. 31, 2021 0    
Balance at beginning of period at Dec. 31, 2021 $ 0    
Balance at end of period (in shares) at Sep. 30, 2022 0    
Balance at end of period at Sep. 30, 2022 $ 0    
Balance at beginning of period (in shares) at Dec. 31, 2021 142,241,000 142,241,000  
Balance at beginning of period at Dec. 31, 2021 $ 149,679 $ 352,881 (203,202)
Total stockholders’ equity      
Issuance of common stock upon exercise of stock options (in shares) 1,680,000 1,680,000  
Issuance of common stock upon exercise of stock options $ 2,244 $ 2,244  
Issuance of common stock under the employee stock purchase plan (in shares) 497,000    
Issuance of common stock under the employee stock purchase plan $ 2,027    
Vesting of restricted stock units (in shares) 207,000    
Stock-based compensation expense $ 22,696 $ 22,696  
Net loss $ (49,114)   (49,114)
Balance at end of period (in shares) at Sep. 30, 2022 144,625,000 144,625,000  
Balance at end of period at Sep. 30, 2022 $ 127,532 $ 379,848 (252,316)
Balance at beginning of period (in shares) at Jun. 30, 2022 0    
Balance at beginning of period at Jun. 30, 2022 $ 0    
Balance at end of period (in shares) at Sep. 30, 2022 0    
Balance at end of period at Sep. 30, 2022 $ 0    
Balance at beginning of period (in shares) at Jun. 30, 2022   143,890,000  
Balance at beginning of period at Jun. 30, 2022 134,719 $ 371,844 (237,125)
Total stockholders’ equity      
Issuance of common stock upon exercise of stock options (in shares)   559,000  
Issuance of common stock upon exercise of stock options $ 688 $ 688  
Vesting of restricted stock units (in shares) 176,000    
Stock-based compensation expense $ 7,316 $ 7,316  
Net loss $ (15,191)   (15,191)
Balance at end of period (in shares) at Sep. 30, 2022 144,625,000 144,625,000  
Balance at end of period at Sep. 30, 2022 $ 127,532 $ 379,848 $ (252,316)